Toxicity of extracellular cGAMP and its analogs to T cells is due to SLC7A1-mediated import
Sudaryo, V.; R. Carvalho, D.; Lee, J. M.; Carozza, J. A.; Cao, X.; Cordova, A. F.; Li, L.
Show abstract
STING agonists are promising innate immune therapies and can synergize with adaptive immune checkpoint blockade therapies for cancer treatment, but their effectiveness is limited by the toxicity to activated T cells. An important class of STING agonists are analogs of the endogenous STING agonist, cGAMP, and while transporters for these small molecules are known in some cell types, how they enter and kill T cells remains unknown. Here, we identify the cationic amino acid transporter SLC7A1 as the dominant transporter of cGAMP and its analogs in activated primary mouse and human T cells. T cells upregulate this transporter upon activation and rapid proliferation to meet their high metabolic demand, but this comes at the cost of enabling increased transport and toxicity of cGAMP. To circumvent the essentiality of SLC7A1 to proliferating T cells, we found that the residues responsible for cGAMP transport are separate from the arginine binding pocket allowing us to perturb cGAMP transport and STING-activation mediated killing without impacting arginine transport. These results suggest that SLC7A1 is a potential target for alleviating T cell toxicity associated with cGAMP and its analogs.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Dual Ribosome Profiling reveals metabolic limitations of cancer and stromal cells in thetumor microenvironment 96%
- CRISPR screens and lectin microarrays identify novel high mannose N-glycan regulators 96%
- Phytic Acid (InsP6) Activates HDAC3 Epigenetic Axis to Maintain Intestinal Barrier Function 95%
Similar papers in this journal
Similar papers in this journal
Similar papers in this journal
- Pharmacological modulators of epithelial immunity uncovered by synthetic genetic tracing of SARS-CoV-2 infection responses 96%
- A new universal chimeric-antigen receptor (CAR)- fragment antibody binder (FAB) split system for cancer immunotherapy 95%
- Modulating immune cell fate and inflammation through CRISPR-mediated DNA methylation editing 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.